Kei Koizumi
Hamamatsu, Japan
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 31 publications
Correction: Cost-effectiveness analysis of the Oncotype DX Breast Recurrence Score® test among node-negative early breast cancer patients in Japan.
Journal: Breast cancer (Tokyo, Japan)
Published: August 21, 2026
Quality-of-life assessment in the randomized JBCRG-M06/EMERALD study of eribulin plus dual HER2 blockade in HER2-positive locally advanced or metastatic breast cancer.
Journal: Breast cancer (Tokyo, Japan)
Published: March 30, 2026
Efficacy and safety of eribulin mesylate vs. docetaxel or paclitaxel, combined with trastuzumab and pertuzumab, as first-line treatment for HER2-positive locally advanced or metastatic breast cancer: updated subgroup analyses of JBCRG-M06/EMERALD.
Journal: Breast cancer research and treatment
Published: December 26, 2025
Cost-effectiveness analysis of the Oncotype DX Breast Recurrence Score® test among node-negative early breast cancer patients in Japan.
Journal: Breast cancer (Tokyo, Japan)
Published: July 31, 2025
Correction: Real‑world evidence from Japan regarding survival outcomes and treatment sequence in patients receiving CDK4/6 inhibitor plus endocrine therapy as first‑ or second‑line treatment for hormone receptor-positive, HER2‑negative advanced or metastatic breast cancer.
Journal: Breast cancer (Tokyo, Japan)
Published: June 23, 2025
Health-related quality of life and physical activity collected via mobile application and wearable device in patients with HR +/HER2 - advanced breast cancer treated with palbociclib plus endocrine therapy or endocrine therapy alone: 6-month longitudinal study (JBCRG-26).
Journal: Breast cancer (Tokyo, Japan)
Published: January 28, 2025
Real-world evidence from Japan regarding survival outcomes and treatment sequence in patients receiving CDK4/6 inhibitor plus endocrine therapy as first- or second-line treatment for hormone receptor-positive, HER2-negative advanced or metastatic breast cancer.
Journal: Breast cancer (Tokyo, Japan)
Published: January 28, 2025
Trastuzumab-Pertuzumab Plus Eribulin or Taxane as First-Line Chemotherapy for Human Epidermal Growth Factor 2-Positive Locally Advanced/Metastatic Breast Cancer: The Randomized Noninferiority Phase III EMERALD Trial.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: January 09, 2025
A multicenter, phase II trial of triplet antiemetic therapy with palonosetron, aprepitant, and olanzapine for highly emetogenic chemotherapy in breast cancer (PATROL-II).
Journal: Scientific reports
Published: July 31, 2024
Status of incremental costs of first-line treatment recommended in Japanese clinical guidelines for metastatic breast cancer patients.
Journal: Japanese journal of clinical oncology
Published: June 19, 2024
UBL3 overexpression enhances EV-mediated Achilles protein secretion in conditioned media of MDA-MB-231 cells.
Journal: Biochemical and biophysical research communications
Published: May 31, 2024
The Japanese Breast Cancer Society Clinical Practice Guidelines for systemic treatment of breast cancer, 2022 edition.
Journal: Breast cancer (Tokyo, Japan)
Published: August 10, 2023
Last Updated: 09/26/2026